AbbVie (ABBV) Tops Q3 EPS by 3c, Lifts FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Call Buying Activity in AbbVie (ABBV) Targets 3% Upside in Shares Into Mid-November Ahead Various Drug Trials -Susquehanna
October 30, 2017 2:39 PM EDTSusquehanna option strategist Alison Edwards notes call buying in AbbVie (NYSE: ABBV) ahead of various drug trials, as investors purchased Nov 91 Calls with roughly 7,500 trading for $1.25, targeting 3% upside into mid-Nov.
... More